Geoffrey I. Shapiro

Oncology

450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 281 publications

Defective microhomology-mediated end joining in SMARCB1-deficient tumors.

Defective microhomology-mediated end joining in SMARCB1-deficient tumors.

Journal: Science advances

Published: August 14, 2026

A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.

A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.

Journal: Cancer research communications

Published: July 20, 2026

PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.

PTEN deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer.

Journal: The Journal of clinical investigation

Published: July 07, 2026

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 07, 2026

AI-Enhanced Adaptive Virtual Screening Platform Enabling Exploration of 69 Billion Molecules Discovers Structurally Validated FSP1 Inhibitors.

AI-Enhanced Adaptive Virtual Screening Platform Enabling Exploration of 69 Billion Molecules Discovers Structurally Validated FSP1 Inhibitors.

Journal: bioRxiv : the preprint server for biology

Published: April 03, 2026

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Journal: Cancer

Published: March 21, 2026

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: March 18, 2026

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer.

Journal: bioRxiv : the preprint server for biology

Published: February 27, 2026

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.

Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors.

Journal: The New England journal of medicine

Published: February 25, 2026

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 19, 2026

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Journal: JCO precision oncology

Published: December 05, 2025

Defective Microhomology-Mediated End-joining in SMARCB1-Deficient Tumors.

Defective Microhomology-Mediated End-joining in SMARCB1-Deficient Tumors.

Journal: bioRxiv : the preprint server for biology

Published: December 03, 2025

Showing 1-12 of 281

Last Updated: 09/26/2026